PMV Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	39.13	37.98	40.88	38.53	109.12	173.29
Short-Term Investments	54.42	74.96	128.58	165.35	132.76	124.7
Cash & Short-Term Investments	93.55	112.94	169.45	203.88	241.88	297.99
Cash Growth	-41.67%	-33.35%	-16.89%	-15.71%	-18.83%	-17.55%
Other Current Assets	2.23	2.28	6.2	3.53	5.13	3.3
Total Current Assets	95.78	115.23	175.66	207.41	247.01	301.29
Net Property, Plant & Equipment	0.49	1.04	1.55	19.05	20.49	13.15
Long-Term Investments	-	-	13.84	25.51	2.5	16.91
Other Long-Term Assets	0.3	0.3	0.24	0.19	0.31	0.22
Total Assets	96.56	116.56	191.29	252.15	270.31	331.57
Accounts Payable	1.63	3.16	6.58	3.24	3	3.19
Accrued Expenses	6.67	7.86	7.44	9.94	7.31	8.63
Current Portion of Leases	0.29	0.4	0.35	0.85	0.53	0.4
Total Current Liabilities	8.6	11.42	14.37	14.03	10.83	12.22
Long-Term Leases	-	0.44	0.84	12.43	13.45	10.79
Total Long-Term Liabilities	-	0.44	0.84	12.43	13.45	10.79
Total Liabilities	8.6	11.85	15.21	26.46	24.28	23.01
Additional Paid-in Capital	552.47	551.08	544.65	535.47	487.52	476.36
Accumulated Other Comprehensive Income	-0.02	0.08	0.14	0.22	-0.45	-0.08
Retained Earnings	-464.49	-446.45	-368.71	-310	-241.04	-167.73
Shareholders' Equity	87.97	104.71	176.08	225.69	246.03	308.56
Total Liabilities & Equity	96.56	116.56	191.29	252.15	270.31	331.57
Total Debt	0.29	0.84	1.19	13.29	13.98	11.19
Net Cash (Debt)	93.26	112.11	168.26	190.59	227.9	286.79
Net Cash Growth	-16.81%	-33.38%	-11.72%	-16.37%	-20.54%	-20.65%
Net Cash Per Share	1.76	2.13	3.26	3.97	5.00	6.35
Book Value	87.97	104.71	176.08	225.69	246.03	308.56
Book Value Per Share	1.66	1.99	3.41	4.70	5.40	6.84
Tangible Book Value	87.97	104.71	176.08	225.69	246.03	308.56
Tangible Book Value Per Share	1.66	1.99	3.41	4.70	5.40	6.84

SEC Filings: 10-K · 10-Q